The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population

Blonde Lawrence; Burudpakdeeb Chakkarin; Divino Victoria; Bookhart Brahim; Cai Jennifer; Pfeifer Michael; Coleman Craig I

首页> 外文期刊>Current medical research and opinion >The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population

【24h】

The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population

机译：非医用开关对在商业上保险的美国人群中蜜蜜醇中的2型糖尿病患者的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: To assess the impact of non-medical switch (NMS) from canagliflozin on antihyperglycemic agent (AHA) medication taking behavior.

机译：目的：评估非医用开关（NMS）对羊皮脂素对抗血糖药物（AHA）药物服用行为的影响。

著录项

来源
《Current medical research and opinion》 |2018年第8期|共11页
作者
Blonde Lawrence; Burudpakdeeb Chakkarin; Divino Victoria; Bookhart Brahim; Cai Jennifer; Pfeifer Michael; Coleman Craig I;
展开▼
作者单位

Ochsner Med Ctr Frank Riddick Diabet Inst Dept Endocrinol New Orleans LA USA;

IQVIA 8280 Willow Oaks Corp Dr STE 775 Fairfax VA 22031 USA;

IQVIA 8280 Willow Oaks Corp Dr STE 775 Fairfax VA 22031 USA;

Janssen Sci Affairs LLC Titusville NJ USA;

Janssen Sci Affairs LLC Titusville NJ USA;

Janssen Med Affairs LLC Titusville NJ USA;

Univ Connecticut Sch Pharm Storrs CT USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词
Diabetes mellitus; type 2; retrospective studies; sodium-glucose transporter 2 inhibitors; canagliflozin; drug utilization; non-medical switching;

机译：糖尿病;2型;回顾性研究;钠 - 葡萄糖转运蛋白2抑制剂;蜜饯;药物利用;非医疗切换;

相似文献

外文文献
中文文献
专利

1. The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population [J] . Blonde Lawrence, Burudpakdeeb Chakkarin, Divino Victoria, Current medical research and opinion . 2018,第8期

机译：非医用开关对在商业上保险的美国人群中蜜蜜醇中的2型糖尿病患者的影响
2. Medical Claim Cost Impact of Improved Diabetes Control for Medicare and Commercially Insured Patients with Type 2 Diabetes [J] . Bruce S. Pyenson, Kathryn Fitch, Kosuke Iwasaki Journal of Managed Care & Specialty Pharmacy . 2015,第8期

机译：医疗保险费用改善对2型糖尿病医疗保险和商业保险患者的糖尿病控制的影响
3. Medical Claim Cost Impact of Improved Diabetes Control for Medicare and Commercially Insured Patients with Type 2 Diabetes [J] . Bruce S. Pyenson, Kathryn Fitch, Kosuke Iwasaki Journal of Managed Care & Specialty Pharmacy . 2015,第8期

机译：医疗保险费用改善对2型糖尿病医疗保险和商业保险患者的糖尿病控制的影响
4. Clinical and metabolic parameters associated with time in ranges and glucose variability in patients with type 2 diabetes treated with insulin [C] . Julia F. Semenova, Maksim V. Dashkin Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：胰岛素治疗的2型糖尿病患者的临床和代谢参数与时间范围和葡萄糖变异性相关
5. Incidence of hypoglycemia and associated costs in Type 1and Type 2 diabetes patients treated with insulin analogs vs. human insulin: A retrospective cohort study. [D] . Shah, Hiren P. 2014

机译：使用胰岛素类似物与人胰岛素治疗的1型和2型糖尿病患者的低血糖发生率和相关费用：一项回顾性队列研究。
6. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin [O] . Aika Miya, Akinobu Nakamura, Kyu Yong Cho, 2021

机译：内源性胰岛素分泌对用蜜胶（Canagliflozin Plus Teneligliptin治疗2型糖尿病患者葡萄糖变异性的影响
7. Medical Claim Cost Impact of Improved Diabetes Control for Medicare and Commercially Insured Patients with Type 2 Diabetes [O] . Kathryn Fitch, Bruce S. Pyenson, Kosuke Iwasaki 2013

机译：医疗索赔改善Medicare＆Medicares和2型糖尿病患者的糖尿病控制的成本影响

The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population

摘要

著录项

相似文献

相关主题

期刊订阅